Abstract
Diabetic ketoacidosis (DKA) is an acute and significant life-threatening complication of diabetes. The association of sodium-glucose cotransporter-2 inhibitors (SGLT2i) with euglycemic diabetic ketoacidosis (EDKA) has been well reported. This literature review was conducted to understand the mechanism of EDKA and identify the potential risk factors and precipitants for patients taking SGLT2i. After reviewing the published literature between 2010 and 2020, 32 articles are included in the final review. The underlying mechanism is mainly enhanced lipolysis and ketone body reabsorption. SGLT2i also stimulates pancreatic alpha cells and inhibits beta cells, causing an imbalance in glucagon/insulin levels, further contributing to lipolysis and ketogenesis. Most patients were diagnosed with blood glucose less than 200 mg/dL, blood pH <7.3, increased anion gap, increased blood, or urine ketones. Perioperative fasting, pancreatic etiology, low carbohydrate or ketogenic diet, obesity, and malignancy are identified precipitants in this review. As normoglycemia can conceal the underlying acidosis, physicians should be cognizant of the EDKA diagnosis and initiate prompt treatment. Patient education on risk factors and triggers is recommended to avoid future events.
Highlights
BackgroundDiabetic ketoacidosis (DKA) is a common, life-threatening complication seen in patients with type 1 and type 2 diabetes mellitus (T2DM) [1]
In a subgroup of patients with diabetes, ketonemia and metabolic acidosis occur without a concurrent rise in blood sugar levels (
The risk factors for EDKA in patients taking sodium-glucose cotransporter-2 inhibitors (SGLT2i) are diverse, and many preexisting or acute conditions can act as precipitants placing patients at risk for EDKA
Summary
Diabetic ketoacidosis (DKA) is a common, life-threatening complication seen in patients with type 1 and type 2 diabetes mellitus (T2DM) [1]. In a subgroup of patients with diabetes, ketonemia and metabolic acidosis occur without a concurrent rise in blood sugar levels (
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.